Meeting
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
Authors
Carrie Ho
Fred Hutchinson Cancer Center, Seattle, WA
Carrie Ho , Jonathan R. Fromm , Min Fang , Brian G. Till , Mazyar Shadman , Andrew Cowan , Ryan C. Lynch , Vicky Wu , Jenna M. Voutsinas , Heather A. Rasmussen , Katharine Blue , Chaitra Shankar Ujjani , Andrei R. Shustov , Ryan Daniel Cassaday , Ajay K. Gopal , Stephen Douglas Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02541565
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7561)
DOI
10.1200/JCO.2023.41.16_suppl.7561
Abstract #
7561
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2018 ASCO Annual Meeting
Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.
First Author: He Huang
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
First Author: Michael Dickinson